Scholars@Duke
Rebecca A Previs

Rebecca A Previs

Adjunct Assistant Professor in the Department of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
rebecca.previs@duke.edu
Division of Gynecologic Oncolo, DUMC Box 3079, Durham, NC 27710

Scholarly Works - Other

Data from Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer

Other · December 11, 2025 <div>AbstractBackground:<p>Differential access to quality care is associated with racial disparities in ovarian cancer survival. Few studies have examined the association of multiple healthcare access (HCA) dimensions with racial dispar ... Full text Cite

Supplementary Figure from Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer

Other · December 11, 2025 Supplementary Figure from Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer ... Full text Cite

Data from Healthcare Access Domains Mediate Racial Disparities in Ovarian Cancer Treatment Quality in a US Patient Cohort: A Structural Equation Modelling Analysis

Other · November 26, 2025 <div>AbstractBackground:<p>Ovarian cancer survival disparities have persisted for decades, driven by lack of access to quality treatment. We conducted structural equation modeling (SEM) to define latent variables representing three heal ... Full text Cite

Supplementary Tables 1-3, Supplementary Figures 1-2, and Supplementary Methods from Healthcare Access Domains Mediate Racial Disparities in Ovarian Cancer Treatment Quality in a US Patient Cohort: A Structural Equation Modelling Analysis

Other · November 26, 2025 <p>Supplemental Figure 1: Participant flowchart for Non-Hispanic Black, Hispanic and Non-Hispanic White ovarian cancer patients. Supplemental Table 1: Diagnosis Codes for patient comorbid conditions. Supplemental Methods: This supplemental ma ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · November 24, 2025 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · November 24, 2025 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

TABLE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Estimates of the associations between HCA dimensions, patient race and ethnicity, and EOL care quality outcomes on entire study cohort (<i>N</i> = 4,646), subcohort of patients that died from ovarian cancer (<i>N</i&gt ... Full text Cite

TABLE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Baseline characteristics of patients with ovarian cancer who died during study follow-up stratified by race and ethnicity (<i>N</i> = 4,646)</p> ... Full text Cite

Supplementary Table 5 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio (RR) for receipt of any chemotherapy within 14 days of death with interaction term between accessibility score and patient race</p> ... Full text Cite

TABLE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Baseline characteristics of patients with ovarian cancer who died during study follow-up stratified by race and ethnicity (<i>N</i> = 4,646)</p> ... Full text Cite

FIGURE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Participant flowchart for NHB, Hispanic and NHW patients with ovarian cancer, SEER-Medicare 2008–2015. Percentage of NHB patients presented for sensitivity purposes.</p> ... Full text Cite

TABLE 3 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Adjusted count ratio estimates of the associations between HCA dimensions, patient race and ethnicity, and counts of EOL care quality outcomes as count ratios, from fully-adjusted<a href="#tb3fn1" target="_blank"><sup>a</sup ... Full text Cite

Supplementary Table 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Patient, census tract, and regional level variables measuring dimensions of healthcare affordability, availability and accessibility</p> ... Full text Cite

TABLE 3 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Adjusted count ratio estimates of the associations between HCA dimensions, patient race and ethnicity, and counts of EOL care quality outcomes as count ratios, from fully-adjusted<a href="#tb3fn1" target="_blank"><sup>a</sup ... Full text Cite

Supplementary Table 4 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio estimates of the associations between HCA dimensions, patient race/ethnicity, and EOL care quality outcomes</p> ... Full text Cite

Supplementary Table 5 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio (RR) for receipt of any chemotherapy within 14 days of death with interaction term between accessibility score and patient race</p> ... Full text Cite

Data from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <div>Abstract<p>This study investigated the association between health care access (HCA) dimensions and racial disparities in end-of-life (EOL) care quality among non-Hispanic Black (NHB), non-Hispanic White (NHW), and Hispanic patients ... Full text Cite

TABLE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Estimates of the associations between HCA dimensions, patient race and ethnicity, and EOL care quality outcomes on entire study cohort (<i>N</i> = 4,646), subcohort of patients that died from ovarian cancer (<i>N</i&gt ... Full text Cite

Supplementary Table 4 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio estimates of the associations between HCA dimensions, patient race/ethnicity, and EOL care quality outcomes</p> ... Full text Cite

Data from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <div>Abstract<p>This study investigated the association between health care access (HCA) dimensions and racial disparities in end-of-life (EOL) care quality among non-Hispanic Black (NHB), non-Hispanic White (NHW), and Hispanic patients ... Full text Cite

FIGURE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Participant flowchart for NHB, Hispanic and NHW patients with ovarian cancer, SEER-Medicare 2008–2015. Percentage of NHB patients presented for sensitivity purposes.</p> ... Full text Cite

FIGURE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>EOL care quality outcomes by patient race and ethnicity (<i>N</i> = 4,646). ICU stay and ER visit outcomes not shown due to cell suppression rules. Outcomes that differ by patient race/ethnicity (<i>χ</i><sup> ... Full text Cite

FIGURE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>EOL care quality outcomes by patient race and ethnicity (<i>N</i> = 4,646). ICU stay and ER visit outcomes not shown due to cell suppression rules. Outcomes that differ by patient race/ethnicity (<i>χ</i><sup> ... Full text Cite

Supplementary Table 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Patient, census tract, and regional level variables measuring dimensions of healthcare affordability, availability and accessibility</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite